Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Chem Biol. 2010 Aug;14(4):440-6. doi: 10.1016/j.cbpa.2010.05.005.

Inhibiting Plasmodium cytochrome bc1: a complex issue.

Author information

  • 1Department of Chemistry, University of Liverpool, Oxford Street, Liverpool L69 7ZD, UK.

Abstract

The cytochrome bc(1) complex is a key mitochondrial enzyme that catalyses transfer of electrons maintaining the membrane potential of mitochondria. Currently, atovaquone is the only drug in clinical use targeting the Plasmodium falciparum bc(1) complex. The rapid emergence of resistance to atovaquone resulted in a costly combination with proguanil (Malarone), limiting its widespread use in resource-poor disease-endemic areas. Cheaper alternatives that can overcome resistance are desperately required. Here we describe recent advances of bc(1)-targeted inhibitors that include hydroxynaphthoquinones (atovaquone analogues), pyridones (clodipol analogues), acridine related compounds (acridinediones and acridones) and quinolones. Significantly, many of these developmental compounds demonstrate little cross resistance with atovaquone-resistant parasite strains, and selected classes have excellent oral activity profiles in rodent models of malaria.

2010 Elsevier Ltd. All rights reserved.

PMID:
20570550
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk